Breaks Categories: News

WednesdayMay 04, 2022 1:25 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Transition from Pure-Play Pharma R&D Firm Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. The piece details InMed Pharmaceuticals and its continued “transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future,” the report reads. “INM also made notable advances in its pharmaceutical drug development programs, including its ongoing 755-201-EB Phase II…

Continue Reading

TuesdayMay 03, 2022 12:11 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Launch of Physician-Focused Ads as Part of Large-Scale Campaign Around sugarBEAT(R)

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that its U.K. licensee, MySugarWatch, as part of a large scale awareness campaign for the company’s sugarBEAT non-invasive continuous glucose monitor, has launched a series of ads in one the U.K.’s preeminent physician and pharmacist education resources, MIMS. “We are very pleased to see our U.K. licensee taking significant steps toward supporting the commercialization efforts around sugarBEAT,” said Nemaura’s CEO Faz Chowdhury, Ph.D. “We are committed to supporting MySugarWatch to ensure the success…

Continue Reading

ThursdayApr 28, 2022 1:35 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced its receipt of approval from the Spanish Agency for Medicines and Health Products (“AEMPS”) Competent Authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for CNSP’s potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. “We continue to build momentum in our potentially pivotal study of Berubicin, and importantly advance toward bringing…

Continue Reading

ThursdayApr 28, 2022 12:47 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Patent Portfolio with Novel Cannabinoid Analogs, Initiates Strategic Research Collaboration Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the publication of a patent application in North America. The application has broad claims directed to the molecular structure, uses and methods of manufacturing of several cannabinoid analogs. Describing several new cannabinoid-related chemical compounds, the broad patent application, if granted, allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities (“NCEs”). “We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs,” said Eric Hsu, SVP,…

Continue Reading

TuesdayApr 26, 2022 1:16 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New CFO, Corporate Secretary

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced the appointment of a new chief financial officer and corporate secretary. The company named François C. Desrosiers, B. Com (Spec.) and FCSI, as Rryah CFO and corporate; the appointment is subject to approval  by the Canadian Securities Exchange (“CSE”). Desrosiers brings impressive experience in senior executive leadership roles to his new role with RYAH. He has served as cofounder, president, CEO and director at Northcore Resources Inc.; corporate secretary and officer…

Continue Reading

MondayApr 25, 2022 12:45 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at Planet MicroCap Showcase 2022

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that it will be presenting at the Planet MicroCap Showcase 2022, which is slated to take place from May 3-5, 2022, at the Bally’s Hotel & Casino in Las Vegas, Nevada. Nemaura’s Dr. Faz Chowdhury will present virtually at the event, with his presentation scheduled to begin at 9 a.m. PT on Wednesday, May 4. Interested parties should visit https://ibn.fm/5QyWV and https://ibn.fm/9wFBj to register for the event, book one-on-one meetings and access Nemaura’s presentation. To view the full press…

Continue Reading

FridayApr 22, 2022 10:48 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the KCSA Psychedelics Virtual Investor Conference. Drysdale’s presentation is slated to begin at 11:00 a.m. ET on Thursday, April 28, 2022, at the live, interactive online event designed to invite investors to ask the company questions in real-time. Interested parties should visit https://ibn.fm/2G8rh to register for the conference and access the webcast. The archived webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/G32LV About Cybin…

Continue Reading

FridayApr 22, 2022 10:08 am

BioMedNewsBreaks — AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) to Conduct Key Research with TransBIOTech, Names New COO

AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) has partnered with TransBIOTech, a publicly supported preclinical research organization, in a project to research cannabinoids and other early-stage commercial programs. TransBIOTech works with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (“NSERC”) in collaboration with the Canadian Institutes of Health Research (“CIHR”). AREV and TransBIOTech will work together to establish a foundation for further research focused on specific understandings of the company’s recent chemical entity development including initial toxicity, pharmacokinetics and metabolism modeling essential for human studies and eventual commercialization. In addition, AREV also…

Continue Reading

ThursdayApr 21, 2022 1:48 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Advisory Board Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A),a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of David Allan and John McGraw, PhD, MSc, to the company’s advisory board. Allan is the 2017 recipient of the prestigious Julia Levy Award and will collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals. McGraw has more than 20 years of executive experience commercializing health technologies, including medical devices, therapeutics and health services. “Mr. Allan and Dr. McGraw both have impressive careers in the…

Continue Reading

ThursdayApr 21, 2022 1:15 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has partnered with Clinilabs Drug Development Corporation to work on its upcoming phase 1/2a clinical trial of CYB003. Clinilabs is a global, full-service contract research organization that has built a reputation for its expertise in central nervous system drug development. Derived from psilocybin, Cybin’s CYB003 is part of a family of molecules called indolamines that include common neurotransmitters such as serotonin. The molecule will be the first psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). According to…

Continue Reading